Executive Vice President and Chairman
Pharmaceutical Research Institute
Shaker A Mousa finished his PhD from Ohio State University, College of Medicine, Columbus, OH and Post-doctoral Fellowship, University of Kentucky, Lexington KY. He also received his MBA from Widener University, Chester, PA. He is currently an endowed tenure Professor and Executive Vice President and Chairman of the Pharmaceutical Research Institute and Vice Provost for Research at ACPHS. Prior to his academic career, he was a senior Scientist and fellow at The DuPont Pharmaceutical Company for 17 years, where he contributed to the discovery and development of several FDA approved and globally marketed diagnostics and therapeutics. He holds over 350 US and International Patents discovering novel anti-angiogenesis strategies, antithrombotics, anti-integrins, anti-cancer, and non-invasive diagnostic imaging approaches employing various nanotechnology platforms. His has published more than 1,000 journal articles, book chapters, published patents, and books as editor and author. He is a member of several NIH study sections, and the Editorial Board Member of several high impact Journals. His research has focused on diagnostics and therapeutics of angiogenesis-related disorders, thrombosis, vascular and cardiovascular diseases.
Dr. Mousa's current research interests include: Adhesion molecules in health and diseases, Novel therapeutic and diagnostic targets, Treatment and prevention of ischemic and coronary artery diseases, Angiogenesis modulation, vascular and tissue remodeling, and novel anti-platelet, anti-thrombotic and anti-ischemic therapies. Dr. Mousa received a Ph.D. in Pharmacology from The Ohio State University, completed postdoctoral research in Cardiovascular Pharmacology at the University of Kentucky and earned his MBA from Widener University. A native of Alexandria, Egypt, he received his B.Pharm. and M.Sc. degrees from Alexandria University. He was elected a fellow of the American College of Cardiology (FACC) and a fellow of the National Academy of Clinical Biochemistry (FACB), and is a member of several national and international societies. He was recently awarded grants through the U.S. Department of Defense and the National Institute of Health.